# CT characteristics of pheochromocytoma - Relevance for the evaluation of adrenal incidentaloma

Canu, Letizia; Van Hemert, Janna A W; Kerstens, Michiel; Hartman, Robert; Khanna, Aakanksha; Kraljevic, Ivana; Kastelan, Darko; Badiu, Corin; Ambroziak, Urszula; Tabarin, Antoine; Haissaguerre, Magalie; Buitenwerf, Edward; Visser, Anneke; Mannelli, Massimo; Arlt, Wiebke; Chortis, Vasileios; Bourdeau, Isabelle; Gagnon, Nadia ; Buchy, Marie; Borson-Chazot, Francoise

*DOI:*
10.1210/jc.2018-01532



*Document Version*
Peer reviewed version

# CT characteristics of pheochromocytoma - Relevance for the evaluation of adrenal incidentaloma

Arlt, Wiebke; Chortis, Vasileios

# CT characteristics of pheochromocytoma – Relevance for the evaluation of adrenal incidentaloma

Letizia Canu[1,2], Janna A.W. Van Hemert[1], Michiel Kerstens[3], Robert P. Hartman[4], Aakanksha Khanna[5], Ivana Kraljevic[6], Darko Kastelan[6], Corin Badiu[7], Urszula Ambroziak[8], Antoine Tabarin[9], Magalie Haissaguerre[9], Edward Buitenwerf[3], Anneke Visser[10], Massimo Mannelli[2], Wiebke Arlt[11], Vasileios Chortis[11], Isabelle Bourdeau[12], Nadia Gagnon[12], Marie Buchy[13], Francoise Borson-Chazot[13], Timo Deutschbein[14], Martin Fassnacht[14,15], H. Alicja Hubalewska Dydejczyk[16], Marcin Motyka[16], Ewelina Rzepka[16], Ruth T. Casey[17], Benjamin G. Challis[17], Marcus Quinkler[18], Laurent Vroonen[19], Ariadni Spyroglou[20,21], Felix Beuschlein[20,21], Cristina Lamas[22], William F. Young[5], Irina Bancos[5], Henri J.L.M. Timmers[1].

1 Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands

2 Department of Experimental and Clinical Biomedical Sciences University of Florence, Florence, Italy

3 Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

4 Department of Radiology, Mayo Clinic, Rochester, Minnesota

5 Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota

6 Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia

7 National Institute of Endocrinology "C. I. Parhon", Bucharest, Romania; "Carol Davila" University of Medicine and Pharmacy, Chair of Endocrinology, Bucharest, Romania

8 Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland

9 Service d'Endocrinologie Hôpital Haut-Lévêque, CHU de Bordeaux, Pessac, France

10 Department of Applied Health Research, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

11 Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom

12 Division of Endocrinology, Center hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada

13 Fédération d'Endocrinologie, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron F-69677, France

14 Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Wuerzburg, Wuerzburg, Germany

15 Comprehensive Cancer Center Mainfranken, University of Wuerzburg, Wuerzburg, Germany

16 Chair and Department of Endocrinology, Jagiellonian University, Collegium Medicum, Krakow, Poland

17 Addenbrooke's Hospital, Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge and NIHR Biomedical Research Center, Cambridge, United Kingdom

18 Endocrinology in Charlottenburg, Berlin, Germany

19 Department of Endocrinology, Center Hospitalier Universitaire de Liège, Liège, Belgium

20 Medizinische Klinik und Poliklinik IV Ludwig-Maximilians-Universität München, Munich, Germany

21 Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, UniversitätsSpital Zürich, Zurich, Switzerland

22 Endocrinology Department, Hospital General Universitario de Albacete, Albacete, Spain

Correspondence: Henri J.L.M. Timmers

Dep. of Internal Medicine, section Endocrinology (471)

Radboud University Nijmegen Medical Center

PO Box 9101

6500 HB Nijmegen, the Netherlands

T +31 243614599

F +31 243614599

Email henri.timmers@radboudumc.nl

The author reports no conflicts of interest in this work.

**Abstract**

Background: Up to 7% of all adrenal incidentalomas (AIs) are pheochromocytomas (PCCs). In the evaluation of AI, it is generally recommended to exclude PCC by measurement plasma free or 24h urinary fractionated metanephrines. However, recent studies suggest to abstain from biochemical exclusion of PCC in cases of lesions with computed tomography (CT) characteristics of an adrenocortical adenoma (ACA).

Aim: To determine the prevalence of PCCs with ACA-like attenuation or contrast washout on CT.

Methods: For this multicenter retrospective study, two central investigators independently analyzed the CT reports of 533 patients with 548 histologically confirmed PCCs. Data on tumor size, unenhanced Hounsfield Units (HU), absolute percentage washout (APW) and relative percentage washout (RPW) were collected besides clinical parameters.

Results: Among the 376 PCCs for which unenhanced attenuation data were available, 374 had an attenuation of >10 HU (99.5%). In the two exceptions (0,5%), unenhanced attenuation was exactly 10 HU, which lies just within the range of ≤10 HU that would suggest a diagnosis of ACA. Of 76 PCCs with unenhanced HU >10 and available washout data, 22 (28,9%) had a high APW and/or RPW, suggestive of ACA.

Conclusion: Based on the lack of PCCs with an unenhanced attenuation of <10 HU, and the low proportion (0,5%) of PCCs with an attenuation of =10 HU, it seems reasonable to abstain from biochemical testing for PCC in AIs with an unenhanced attenuation ≤10 HU. The assessment of contrast washout, however, is unreliable to rule out PCC.

Précis: This retrospective study examines the CT characteristics of 548 pheochromocytomas (PCCs). The findings suggest to avoid biochemical testing for PCC in incidentalomas with unenhanced attenuation ≤10HU.

87 Keywords: pheochromocytoma, paraganglioma, adrenal incidentaloma, computed tomography,
88 guideline, Hounsfield Units, contrast washout.
89

## Introduction

Adrenal pheochromocytomas (PCCs) and extra-adrenal sympathetic paragangliomas are rare tumors that arise from catecholamine producing chromaffin cells [1]. Up to 40% of chromaffin tumors are associated with hereditable tumor syndromes [2-5]. The most accurate diagnostic test for the biochemical diagnosis of these tumors is the measurement of plasma free or 24h urinary fractionated metanephrines [6,7]. Typical symptoms and signs include headache, tremors, palpitations, sweating, and anxiety. However, in up to 25% of patients signs and symptoms are lacking and up to 30% of PCCs are diagnosed following the discovery of an adrenal incidentaloma (AI) [7,8].

The prevalence of AI on thoracic, abdominal and pelvic computed tomography (CT) ranges between 1.0% and 8.7% depending on age [9-14]. The majority of AIs are adrenocortical adenoma (ACA) [12]. Less prevalent causes are myelolipomas, cysts, adrenocortical carcinoma and metastases from other malignancies. PCCs account for up to 7% of AIs [7]. In contrast to situations when significant adrenal hormone secretion or malignancy are suspected, no treatment is indicated for benign non-functioning ACA. In 2016, the European Society of Endocrinology (ESE) in collaboration with the European Network for the Study of Adrenal Tumors (ENSAT) published a guideline to provide clinicians with evidence-based recommendations for clinical management of patients with AIs [7]. This guideline adapts a generally accepted approach in the evaluation of AI by taking into account quantitative CT characteristics. Either an attenuation of ≤10 Hounsfield Units (HU) on an unenhanced CT, or an absolute percentage washout (APW) ≥60% or a relative percentage washout (RPW) ≥40% on a CT with delayed washout after 10-15 min are considered suggestive of ACA. However, the guidelines and an accompanied meta-analysis [15] clearly indicated that the unenhanced CT is the only reliable method to differentiate benign from malignant adrenal tumors. In addition, it was recommended to perform an endocrine work-up for AI, including the measurement of plasma free or 24h urinary fractionated metanephrines. However, it was also discussed that it could be reasonable to avoid biochemical testing for PCC in patients AI with a unenhanced attenuation of ≤10 HU. Nevertheless, the authors

acknowledged that only two small studies were published on this topic [16,17]. The findings in the latter studies require confirmation in a larger number of patients before substantiated statements can be made. It is important to note that PCCs demonstrating an attenuation ≤10 HU have been described in literature, though very uncommonly [18,19]. Hence, in this international multicenter study we retrospectively evaluated the quantitative CT characteristics of PCCs, as indicated in the radiological reports, to assess the prevalence and associated characteristics of PCCs with an ACA-like attenuation on CT scan, taking into account both unenhanced attenuation and contrast washout measurements.

## Methods

*Patients*

We included patients with a histologically proven PCC (single or multiple) who had undergone a pre-operative CT scan, *i.e.* either unenhanced CT (+/- contrast enhanced CT) or contrast washout CT. Patients with post-contrast CT scan only were not eligible for inclusion. Patients had been diagnosed and treated in centers affiliated to ENSAT. Participating ENSAT centers were Mayo Clinic (n=153), Rochester, USA; Radboud University Medical Center, Nijmegen, The Netherlands (n=46); University Hospital Center Zagreb, Zagreb, Croatia (n=43); Carol Davila University of Medicine and Pharmacy, Bucharest, Romania (n=42); Medical University of Warsaw, Warsaw, Poland (n=33); CHU de Bordeaux, Pessac, France (n=29); University Medical Center Groningen, Groningen, The Netherlands (n=21); University Hospital of Florence, Florence, Italy (n=21); University of Birmingham, Birmingham, United Kingdom (n=20); Center hospitalier de l'Université de Montréal, Montreal, Canada (n=19); Hospices Civils de Lyon, Lyon, France (n=17); University Hospital of Wuerzburg, Wuerzburg, Germany (n=17); University Hospital of Krakow, Krakow, Poland (n=16); Cambridge University Hospitals, Cambridge, United Kingdom (n=12); Endocrinology in Charlottenburg, Berlin, Germany (n=12); Center Hospitalier Universitaire de Liege, Liege, Belgium (n=10); Medizinische Klinik und Poliklinik IV Ludwig-Maximilians-Universität München, Munich, Germany (n=10); Hospital General Universitario de

Albacete, Albacete, Spain (n=5). Patients provided informed consent, either under ENSAT or local institutional protocol, when required. Two hundred fourteen patients from the two Dutch centers were also included in a previous study on this topic by Buitenwerf et al.[20]. In the latter study, a central re-evaluation of CT images was performed to calculate unenhanced attenuation, whereas in the current study, both unenhanced attenuation and contrast washout were analyzed based on locally generated CT reports. Additional inclusion criteria were age at diagnosis ≥18 years, a diagnosis in or after the year 2000, availability of the CT report and clinical annotations (age, sex, underlying hereditary syndrome).

*Biochemical testing and imaging*

Biochemical testing, usually by measurement of plasma free or 24h urinary fractionated metanephrines, was performed according to local protocols with corresponding reference values. If metanephrines were not available, 24h urine or plasma catecholamines were utilized, in order of preference. Biochemical phenotypes were categorized as "adrenergic", "noradrenergic" or "normal". The phenotype was classified as "adrenergic" when the increment of metanephrines, relative to the upper limits of normal, exceeded 5% of the combined metanephrine and normetanephrine increments. Patients in whom these criteria were not fulfilled and in whom normetanephrine levels exceeded the upper limits of normal were classified as "noradrenergic" [21]. In addition, CT scans were performed according to local protocols regarding contrast procedure, acquisition and reconstruction parameters and approach to draw the region of interest for HU measurements. Unenhanced, unenhanced and contrast and dedicated adrenal CT scan were included. Dedicated adrenal CT scan requires attenuation measurements before contrast administration, 60s and 10-15 min after contrast injection.

*Evaluation of CT reports*

Anonymized imaging reports of pre-operative CT scans, generated by local radiologists as part of routine diagnostic evaluation, were submitted for central analysis. The reports were evaluated and scored independently by two observers (LC; JVH) who were blinded to the clinical information. Type of CT scan and field of view, number and location of lesions, tumor size, unenhanced HU, APW and RPW were considered. In case multiple unenhanced HU values were mentioned, the highest value was chosen for analysis. When in the local report values for APW/RPW were not mentioned, APW and RPW were calculated according to the formulas below, provided that the required parameters were available.

$$\text{APW} = \frac{HU\ portal\ venous\ phase - HU\ delayed\ phase}{HU\ portal\ venous\ phase - HU\ unenhanced}\ x\ 100\%$$

$$\text{RPW} = \frac{HU\ portal\ venous\ phase - HU\ delayed\ phase}{HU\ portal\ venous\ phase}\ x\ 100\%$$

PCCs were classified as ACA-like based on quantitative CT characteristics in case one of the following criteria were fulfilled: 1. Attenuation on unenhanced CT $\leq$10 HU or 2. Attenuation on unenhanced CT $\geq$10 HU and APW ≥60% and/or RPW ≥40%.

*Data management and statistical analysis*

Statistical analysis was performed with SPSS 17.0 for Windows. Clinical characteristics were compared between PCC patients with and without an ACA-like attenuation based on quantitative criteria. Characteristics were compared using an unpaired T test if variables were continuous or a Chi square test if variables were categorical. A two-sided P value of <0.05 was considered statistically significant.

## Results

In total, 1011 cases of PCCs and extra adrenal sympathetic paragangliomas were screened for eligibility by the local investigators at the 18 participating centers. Four hundred and seven cases were excluded, mainly because of the performance of post-contrast CT only (n=305). After

central review, 71 additional cases were excluded based on a diagnosis of extra-adrenal paraganglioma rather than PCC (n=25), lack of CT report (n=21), incomplete CT report (n=14), age <18 years (n=5), lack of histological proof of PCC (n=4) and performance of post-contrast CT only (n=2). Out of the remaining 533 patients with 548 histologically confirmed PCCs, quantitative CT characteristics were available in 368 patients with 382 PCCs (376 unenhanced HU +/- washout and 6 washout only). The clinical characteristics are given in Table 1. Details on CT scan protocols and availability of quantitative data from radiology reports are given in Table 2.

*PCCs with ACA-like attenuation or washout*

Among the 376 PCCs for which unenhanced attenuation was available, 374 had an attenuation of >10 HU (99.5%, Figure 1). In the two exceptions (0,5%), unenhanced attenuation was exactly 10 HU, which lies just within the range of ≤10 HU that would suggest a diagnosis of ACA (supplemental Table 1 [22]). Of these two PCCs, the histology reports were re-evaluated. The first lesion was a PCC with extensive central haemorrhage. The second adrenal contained areas of prominent nodular adrenocortical hyperplasia besides PCC.

Of 76 PCCs with unenhanced HU >10 and available washout, 22 (28,9%) had an APW ≥60% and/or an RPW ≥40%, suggestive of ACA. In one additional PCC APW/RPW was high as well, but unenhanced attenuation was unavailable. The local radiologists reported on six additional lesions with characteristics of ACA. The reasons for this, however, could not be verified, since washout data were unavailable and in the two cases where unenhanced attenuation was mentioned, it was >10 HU.

The PCCs with an unenhanced attenuation of >10 HU and high APW and/or RPW (n=22) did not differ from those with an unenhanced attenuation of >10 HU and low washout (n=54) with respect to sex, tumor size and hereditary syndrome (data not shown).

Two hundred eighty-two out of 548 PCCs (51.4%) were initially discovered as AI in 276 patients. One out of 199 lesions with available quantitative was data was among the two lesions of 10 HU.

In this subgroup, out of 29 PCCs with unenhanced HU >10 and available washout, 10 (34.4%) had a high APW and/or RPW.

## Discussion

We retrospectively evaluated the CT characteristics of PCC in the largest international cohort to date. Our main goal was to determine the prevalence of PCCs with an ACA-like appearance based on either a low unenhanced attenuation or a high contrast washout. The analysis was based on locally generated radiological reports. Unenhanced HU values were available for 376 out of 548 histologically confirmed PCCs, two of which (0,5%) exhibited an attenuation of exactly 10 HU, consistent with an ACA-like attenuation according to recent ESE/ENS@T guidelines. In addition, among 76 PCCs with unenhanced HU >10 and available washout, 22 (28,9%) showed a high APW and/or RPW, wrongfully suggestive of ACA.

In 2016 ESE/ENSAT provided clinical practice guidelines for the management of patients affected by AIs. It was recommended that, as part of the endocrine workup, PCC should be excluded by measurement of plasma free or 24h urinary fractionated metanephrines in all AIs. However, it was discussed that an exception could be made for those cases where a non-contrast-enhanced CT attenuation was ≤10 HU. A disclaimer was made that the evidence to support this exception was very low, referring to two studies that showed a low likelihood of a PCC among adrenal lesions that are radiologically suggestive of ACA [16,17]. Sane et al. [16] examined whether PCC could be ruled out as cause of AIs on the basis of unenhanced attenuation values only. A cohort of 174 patients with AI was evaluated retrospectively. Unenhanced attenuation was available for 115 tumors. Nine patients had a PCC and in none of these tumors the unenhanced HU was below 10. They concluded that routine measurements of metanephrines is unnecessary in an asymptomatic patient with AI, provided that the lesion is of low attenuation, small and homogenous. Schalin-Jantti et al. [17] performed a 5-year prospective follow-up study of 56 patients with 69 lipid-rich (*i.e.* low attenuation) AIs, showing that 24h urinary metanephrines were normal at baseline as well as during follow-up. In addition, Jun et al. [19] studied 251 patients

with AI and had similar results, leading to the conclusion that for small lesions (AI size ≤3 cm) non-contrast CT can substitute for biochemical testing for PCC. Nevertheless, all of the conclusions and recommendations made in these previous studies are based on small subsets of PCCs among cohorts of patients with AIs.

Rather than taking AI as a starting point, in the present study and in one previous report, primarily patients with PCC were selected. Buitenwerf et al.[20] recently conducted a retrospective study including 214 patients affected by 222 histologically proven PCCs. Two expert radiologists re-evaluated the CT scans images independently. Only one PCC out of 222 demonstrated an attenuation value of <10 HU. This was a rare case of ACTH-dependent Cushing disease caused by a PCC. In the current study we found a similarly low prevalence (0,5%) of PCCs with an unenhanced attenuation of ≤10 HU. In fact none of the PCCs unenhanced attenuation was below 10 HU and in only two PCCs it was exactly 10 HU. In these two cases, histology possibly provided some explanation. Hemorrhage, necrosis and additional adrenocortical [23] changes may result in intralesional heterogeneity, emphasizing the importance of selecting the proper region of interest for the assessment of attenuation.

In ~70% of AIs attenuation values are ≤10 HU, illustrating the large number of patients that might benefit from implementing radiological selection to determine in which patients biochemical screening is needed as second line test to rule out PCC [24]. Based on our results, assuming a 7% prevalence of PCC among AIs, approximately 2900 patients with AI and an attenuation value ≤10 HU would need to be biochemically screened in order to diagnose one PCC. In our opinion, this observation justifies omitting biochemical screening in low-attenuation AIs in order to prevent unnecessary costs and false-positive test results.

Besides unenhanced HU, contrast washout rates are routinely used for the evaluation of adrenal lesions. The majority of ACA with an unenhanced HU >10 exhibit a high washout. Conversely, a high washout does not rule out PCC. We found that in almost one third of PCCs with available APW/RPW data, washout was high. This is in line with a previously meta-analysis of ten studies by Woo et al., [25]. They reported a rate of PCCs with a high washout pattern of 35%. Washout data

for AI should therefore not be used to determine whether biochemical testing should be done or not.

There are several limitations to this study. This is a retrospective study of locally generated radiology reports coming from different centers using different CT machines, settings and contrast protocols. Many cases were excluded because of the availability of post-contrast CT scans only. In addition, drawing of the region of interest for the calculation of radiodensity was done at the discretion of the local radiologist. The detail to which different quantitative parameters were reported varied considerably, leading to many missing data. On the other hand, the data were extracted directly from clinical practice, representative for 'real life'.

## Conclusion

Based on the lack of PCCs with an unenhanced attenuation of <10 HU, and the low proportion (0,5%) of PCCs with an attenuation of =10 HU, it seems reasonable to abstain from biochemical testing for PCC in AIs with an unenhanced attenuation ≤10 HU. The assessment of contrast washout, however, is unreliable to rule out PCC.

## Acknowledgments

We thank professor Jacques W.M. Lenders for his critical appraisal of the manuscript.

## Notes

Abbreviations: ACA, adenoma; AIs, adrenal incidentalomas; APW, absolute percentage washout; CT, computed tomography; CTTA, CT texture analysis; ESE, European Society of Endocrinology; HU, Hounsfield units; lp-ACA, lipid-poor adenoma;MRI magnetic resonance imaging; PCCs, pheochromocytomas; RPW, relative percentage washout.

References

1. Lenders JWM, Duh QY, Eisenhofer G, l Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr; Endocrine Society. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. *Journal of Clinical Endocrinology & Metabolism.* 2014;99(6):1915-1942.

2. Berends AMA, Buitenwerf E, de Krijger RR, Veeger NJGM, van der Horst-Schrivers ANA, Links TP, Kerstens MN. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. *Eur J Intern Med.* 2018;51:68-73.

3. Dahia PL, Hao K, Rogus J, Colin C, Pujana MA, Ross K, Magoffin D, Aronin N, Cascon A, Hayashida CY, Li C, Toledo SP, Stiles CD; Familial Pheochromocytoma Consortium. Novel pheochromocytoma susceptibility loci identified by integrative genomics. *Cancer Res.* 2005;65(21):9651-9658.

4. Vicha A, Musil Z, Pacak K. Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. *Curr Opin Endocrinol Diabetes Obes.* 2013;20(3):186-191.

5. Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. *Nat Rev Endocrinol.* 2015;11(2):101-111.

6. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. *Lancet.* 2005;366(9486):665-675.

7. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. *Eur J Endocrinol.* 2016;175(2):G1-g34.

8. Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, Ventz M, Beuschlein F, Reincke M, Reisch N, Quinkler M. Frequent incidental discovery of

phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. *Eur J Endocrinol.* 2009;161(2):355-361.

9. Arnold DT, Reed JB, Burt K. Evaluation and management of the incidental adrenal mass. *Proc (Bayl Univ Med Cent).* 2003;16(1):7-12.

10. Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. *J Clin Endocrinol Metab.* 2011;96(7):2004-2015.

11. Terzolo M, Bovio S, Pia A, Reimondo G, Angeli A. Management of adrenal incidentaloma. *Best Pract Res Clin Endocrinol Metab.* 2009;23(2):233-243.

12. Young WF, Jr. Clinical practice. The incidentally discovered adrenal mass. *N Engl J Med.* 2007;356(6):601-610.

13. Bulow B, Ahren B. Adrenal incidentaloma--experience of a standardized diagnostic programme in the Swedish prospective study. *J Intern Med.* 2002;252(3):239-246.

14. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. *Eur J Endocrinol.* 2003;149(4):273-285.

15. Dinnes J, Bancos I, Ferrante di Ruffano L, Chortis V, Davenport C, Bayliss S, Sahdev A, Guest P, Fassnacht M, Deeks JJ, Arlt W. MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. *Eur J Endocrinol.* 2016;175(2):R51-64.

16. Sane T, Schalin-Jantti C, Raade M. Is biochemical screening for pheochromocytoma in adrenal incidentalomas expressing low unenhanced attenuation on computed tomography necessary? *J Clin Endocrinol Metab.* 2012;97(6):2077-2083.

17. Schalin-Jantti C, Raade M, Hamalainen E, Sane T. A 5-Year Prospective Follow-Up Study of Lipid-Rich Adrenal Incidentalomas: No Tumor Growth or Development of Hormonal Hypersecretion. *Endocrinol Metab (Seoul).* 2015;30(4):481-487.

18. Blake MA, Krishnamoorthy SK, Boland GW, Sweeney AT, Pitman MB, Harisinghani M, Mueller PR, Hahn PF. Low-density pheochromocytoma on CT: a mimicker of adrenal adenoma. *AJR Am J Roentgenol.* 2003;181(6):1663-1668.

19. Jun JH, Ahn HJ, Lee SM, Kim JA, Park BK, Kim JS, Kim JH. Is Preoperative Biochemical Testing for Pheochromocytoma Necessary for All Adrenal Incidentalomas? *Medicine.* 2015;94(45).

20. Buitenwerf E, Korteweg T, Visser A, Haag CMSC, Feelders RA, Timmers HJLM, Canu L, Haak HR, Bisschop PHLT, Eekhoff EMW, Corssmit EPM, Krak NC, Rasenberg E, van den Bergh J, Stoker J, Greuter MJW, Dullaart RPF, Links TP, Kerstens MN. Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study. *Eur J Endocrinol.* 2018.

21. Eisenhofer G, Pacak K, Huynh TT, Qin N, Bratslavsky G, Linehan WM, Mannelli M, Friberg P, Grebe SK, Timmers HJ, Bornstein SR, Lenders JW. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. *Endocr Relat Cancer.* 2011;18(1):97-111.

22. Canu L, Van Hemert JAW., Kerstens M, Hartman RP, Khanna A., Kraljevic I, Kastelan D, Badiu C, Ambroziak U, Tabarin A, Haissaguerre M, Buitenwerf E, Visser A, Mannelli M, Arlt W, Chortis V, Bourdeau I, Gagnon N , Buchy M, Borson-Chazot F, Deutschbein T, Fassnacht M, Hubalewska Dydejczy H. A , Motyka M, Rzepka E, Casey R T, Challis B G, Quinkler M, Vroonen L, Spyroglou A, Beuschlein F, Lamas C, Young W F, Bancos I, Timmers H J L M. Canu_SupdataTab1.tif https://figshare.com/articles/Canu_SupdataTab1_tif/6815768. DOI 10.6084/m9.figshare.6815768.v1

23. Hasassri ME, Pandian TK, Bobr AA, Bancos I, Young WF Jr, Richards ML, Farley DR, Thompson GB, McKenzie TJ. Pheochromocytoma with Synchronous Ipsilateral Adrenal Cortical Adenoma. *World J Surg.* 2017;41(12):3147-3153.

24. Bancos I, Chortis V, Lang K, Prete A, Terzolo M, Fassnacht M, Quinkler M, Kastelan D, Vassiliadi D, Beuschlein F, Ambroziak U, Sitch A, Deekes J, Arlt W. The natural history of adrenal incidentaloma - results from the international prospective multi-centre EURINE-ACT study. In:Endocrine Abstract 2017; 49 GP122.

25. Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Pheochromocytoma as a frequent false-positive in adrenal washout CT: A systematic review and meta-analysis. *Eur Radiol.* 2017.

388 Table 1: Characteristics of patients of whom quantitative CT characteristics were available

| **n=368** | |
|---|---|
| **Sex: male (%)** | 163 (44,2%) |
| **Age at diagnosis: mean±SD (y)** | 54,01± 15,05 |
| **Biochemical phenotype: n (%)** | |
| Adrenergic | 200 (54,3%) |
| Noradrenergic | 111 (30,1%) |
| Normal values | 18 (4,8%) |
| Unknown | 39 (10,5%) |
| **Hereditary syndrome: n (%)** | 60 (16,3%) * |

389 ** RET (n=32), VHL (n=11), NF1 (n=11), SDHB (n=2), SDHD (n=2), MAX (n=1)* and *SDHAF2 (n=1)*

390

391

392

393

394

395

396

397

398

399

400

401

402 Table 2: CT protocols and availability of quantitative data from radiological reports for PCCs

403

| | | | CT scan protocol, nr (%) | | | |
|---|---|---|---|---|---|---|
| | | | **Unenhanced** **94 (17,2)** | **Unenhanced and post-contrast** **117 (21,4)** | **Contrast washout** **148 (27,0)** | **Unknown** **189 (34,5)** |
| **Availability of quantitative data, n (%)** | **Unenhanced HU only** | **298 (54,4)** | 55 (58,5) | 40 (34,2) | 24 (16,2) | 179 (94,7) |
| | **Unenhanced HU and APW/RPW** | **78 (14,2)** | | | 77 (52,0) | 1 (0,5) |
| | **APW/RPW only** | **6 (1,1)** | | | 6 (4,1) | |
| | **None** | **166 (30,3)** | 39 (41,5) | 77 (65,8) | 41(27,7) | 9 (4,8) |

404

405 HU, Hounsfield Units; AWP, absolute percentage washout; RWP, relative percentage washout

406 Figure 1: CT characteristics of PCCs




407

408 NA, not available; high washout, absolute ≥60% and/or relative ≥40%; low washout, absolute <60% and/or relative <40%.

409

**Supplemental data**

Supplemental Table 1: CT characteristics of 25 PCCs ACA-like based on unenhanced HU and washout

HU, Hounsfield Units; AWP, absolute percentage washout; RWP, relative percentage washout

Table



| | |
|---|---|
| **n=368** | |
| **Sex: male (%)** | 163 (44,2%) |
| **Age at diagnosis: mean±SD (y)** | 54,01 ± 15,05 |
| **Biochemical phenotype: n (%)** | |
| Adrenergic | 200 (54,3%) |
| Noradrenergic | 111 (30,1%) |
| Normal values | 18 (4,8%) |
| Unknown | 39 (10,5%) |
| **Hereditary syndrome: n (%)** | 60 (16,3%) * |

Table



| | | | CT scan protocol, nr (%) | | | |
|---|---|---|---|---|---|---|
| | | | Unenhanced | Unenhanced and post-contrast | Contrast washout | Unknown |
| | | | 94 (17,2) | 117 (21,4) | 148 (27,0) | 189 (34,5) |
| Availability of quantitative data, n (%) | Unenhanced HU only | 298 (54,4) | 55 (58,5) | 40 (34,2) | 24 (16,2) | 179 (94,7) |
| | Unenhanced HU and APW/RPW | 78 (14,2) | | | 77 (52,0) | 1 (0,5) |
| | APW/RPW only | 6 (1,1) | | | 6 (4,1) | |
| | None | 166 (30,3) | 39 (41,5) | 77 (65,8) | 41(27,7) | 9 (4,8) |

Figure

Click here to download Figure Canu_Fig1.tif